NEWS & EVENTS
THE LATEST ON PMT
1,000 Emergency Ventilation-Resuscitation Devices Available Immediately
March 19, 2020, Park City, Utah – PMT Partners announced up to 1,000 Oxylator Emergency Ventilation-Resuscitation Devices are available immediately for clinical use. The Oxylator is a small portable ventilation-resuscitation device that runs on compressed oxygen or air.
“Oxylators can serve a variety of roles in hospital and pre-hospital settings,” said James DuCanto, M.D., Anesthesiologist Milwaukee, Wisconsin USA. “These devices can serve for acute resuscitation or ongoing ventilatory support during a surge capacity ventilation occurrence. The technology has helped thousands of patients in the USA, Europe, and Asia and has served in theaters of war.”
Oxylators are patient-responsive and oxygen powered resuscitation/inhalation devices, no electricity is needed. Oxygen, air, or a combination thereof is delivered through a pressure and flow sensing system to provide optimum care. Oxylators may simplify airway management during emergencies and attended short-term ventilation.
“We have 1,000 combined Oxylator HD and Oxylator EMX devices available for hospitals and emergency medical services,” said Larry Kronick, President of PMT Partners. “At this moment, Oxylators are available and more will be made based market demand.”
Product demonstration video links:
Simulated mass casualty video link:
Oxylators are available to hospitals and Emergency Medical Service providers. Oxylators are not sold directly to patients or individuals.
PMT Partners is a private medical device company that designs, develops, commercializes, and distributes technologies to improve patient care. Products available from PMT Partners include the Oxylator, the PowrSyringe Angiographic Injector, and the AirTight Control Syringe.
For more information:
PMT Partners Media Contact:
+1 (954) 457-2450
AirTight Control Syringe Cleared for Sale
PMT Partners announced that the FDA and CE-Mark cleared AirTight Control Syringe was approved for sale, and the company began shipping product on August 14, 2019. The AirTight Control Syringe is intended to inject contrast media or saline during angiographic procedures and offers substantial improvements in injection ergonomics and patient safety as compared to fixed and rotating-luer control syringes commonly used for angiographic injection today.
While fixed-luer syringes offer secure, leak-free connections to catheters and manifolds, their solid, one-piece design makes this connection and disconnection awkward for clinicians.
Rotating-luer syringes have an integrated O-ring design that makes them easier to connect and disconnect, but they are prone to loose, wobbly connections and air leakage, putting patients at risk of air embolism.
The patented AirTight Syringe Control Syringe bridges the gap between fixed and rotating luer angiographic control syringes, offering easy connection and disconnection to catheters and manifolds without compromising patient safety.
PMT Partners' AirTight Platform is protected by U.S. patents 10,207,057; 10,058,656; and other U.S. and foreign pending and issued patents.
For more information about PMT Partners and the company's AirTight Platform, call 1-954-534-9345 or visit www.powrsyringe.com.
Visit PMT at AMP Symposium 2019
August 14-17, 2019
September 7-10, 2019
Visit PMT at CIRSE 2019
Visit PMT at LINC 2020
January 28-31, 2020